March 2, 2010 (FinancialWire) — Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) has named Terry Nida as its Chief Business officer.  He most recently worked as an Executive Consultant for pharmaceutical and biotechnology companies, including such responsibilities as business development.

Nida formerly held positions as chief operating officer at Urigen Pharmaceuticals from 2006 to 2008 and vice president Corporate Development, Marketing and Sales at VIVUS from 1995 to 2006. He also held senior management positions with Carrington Laboratories, Centocor and started his career with Bristol Myers.

California-based Transdel Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. The company’s Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier.

Ketotransdel, Transdel’s lead pain product, has completed a Phase 3 clinical trial and utilizes the Transdel technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts anti-inflammatory and analgesic effects.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.